Trial site
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, 510095, ChinaNot linked to an institution yet
- 19running trials
- 1closed trial
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Phase 11 trial
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Not yet recruiting4 trials
- Enrolling by invitation1 trial
- Withdrawn1 trial
- Lead sponsor
- Daiichi Sankyo4 trials
- Akeso2 trials
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 trials
- Sun Yat-sen University2 trials
- Zhujiang Hospital2 trials
- and 8 more
Running trials
Enrolling by invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624· Phase 2· Sun Yat-sen University· Source
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682· Phase 3· Dizal (Jiangsu) Pharmaceutical Co., Ltd.· Source
Contact: Sherry Hu, MD, PhD
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869· Hoffmann-La Roche· Source
Recruiting
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764· Daiichi Sankyo· Source
Contact: Principal Investigator
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Not yet recruiting
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
NCT06317896· Zhujiang Hospital· Source
Contact: Yinbing Wu, Prof.
Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329· Phase 2· Teligene US· Source
Contact: Xiaoyang Xia
Recruiting
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
NCT06157060· Zhujiang Hospital· Source
Contact: Yinbing Wu, Prof.
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Not yet recruiting
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127· Phase 3· Akeso· Source
Contact: Zhifang Yao, M.D.
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275· Chinese Academy of Sciences· Source
Contact: Shuzhong Cui, MD
Recruiting
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
NCT05334277· Phase 2· Sun Yat-sen University· Source
Contact: Weidong Li
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239· Phase 1· Boehringer Ingelheim· Source
Active, not recruiting
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398· Phase 3· Akeso· Source
Active, not recruiting
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
NCT04922658· Phase 2· Affiliated Cancer Hospital & Institute of Guangzhou Medical University· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error